PanaKare Plus

Manufacturer
Neogen Corporation-Mercer | ALI Pharmaceutical Manufacturing, LLC | Scientific Protein Laboratories LLC
Effective date
2024-01-23
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
10
Source
full-release
Hydrated at
2026-06-01 02:42:47

Label at a glance#

ProductPanaKare Plus
Active ingredientPANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE
Label structure12 sections

Storage and handling

Store tightly closed container in a dry place at temperatures not exceeding 35°C (95°F).

Label contents#

Full prescribing information#

DESCRIPTION SECTION

PanaKare Plus Tablets

Pancreatic Enzyme Concentrate

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

USE IN SPECIFIC POPULATIONS SECTION

FOR ANIMAL USE ONLY

COMPONENTS

Each tablet contains a minimum of:

Lipase..............................9,000 USP units

Protease.........................57,000 USP units

Amylase..........................64,000 USP units

Description:

DESCRIPTION SECTION

PanaKare Plus is a pancreatic enzyme concentrate of porcine origin.

Precautions:

PRECAUTIONS SECTION

Discontinue use in animals with symptoms of sensitivity or allergy.

SPL UNCLASSIFIED SECTION

Made in the USA of U.S. and imported materials

WARNINGS SECTION

KEEP OUT OF REACH OF CHILDREN

INDICATIONS & USAGE SECTION

Indications:

As a digestive aid in replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency.

Directions for use:

Dose is administered before each meal. Estimate dose according to the severity of the condition and weight of the animal.

Average dose/meal:

Dogs: 2-3 tablets

Cats: 1/2-1 tablet

STORAGE AND HANDLING SECTION

Store tightly closed container in a dry place at temperatures not exceeding 35°C (95°F).

SPL UNCLASSIFIED SECTION

Manufactured by: Neogen Corporation

Lexington, KY 40511 859-254-1221

neogen.com

PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 59051-9067-7

PanaKare Plus Tablets

Pancreatic Enzyme Concentrate

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Net Contents: 500 Tablets

PanaKare Plus Tablets 500ctPanaKare Plus Tablets 500ct

PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 59051-9067-5

PanaKare Plus Tablets

Pancreatic Enzyme Concentrate

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Net Contents: 100 Tablets

PanaKare Plus Tablets 100ctPanaKare Plus Tablets 100ct

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1421001lipase 9,000 UNT / amylase 64,000 UNT / protease 57,000 UNT Oral TabletPSN10
1421007PanaKare Plus 9000 UNT / 64,000 UNT / 57,000 UNT Oral TabletPSN10
1421007amylase 64000 UNT / lipase 9000 UNT / protease 57000 UNT Oral Tablet [PanaKare]SBD10
1421001amylase 64000 UNT / lipase 9000 UNT / protease 57000 UNT Oral TabletSCD10
1421001amylase 64,000 UNT / protease 57,000 UNT / lipase 9,000 UNT Oral TabletSY10
1421001amylases 64,000 UNT / endopeptidases 57,000 UNT / lipase 9000 UNT Oral TabletSY10
1421007PanaKare (amylase 64,000 UNT / protease 57,000 UNT / lipase 9,000 UNT) Oral TabletSY10
1421007PanaKare (amylases 64,000 UNT / endopeptidases 57,000 UNT / lipase 9000 UNT) Oral TabletSY10

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0b1603b8-969e-b082-f6f5-ad66d8a6ea8aProduct name220200325
19041f15-771b-3d3a-88fc-f5e2d079cd6dProduct name220200325
1987d950-08e4-4b70-adeb-fb67a71142abProduct name220200325
8825ddf7-1520-4680-b0ee-684e2fa73672Product name220200325
267a6f34-90b4-2f48-3063-4f505d06a7beProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
59051-9067-5PanaKare Plus100 in 1 BOTTLE, PLASTICTABLET10010
59051-9067-7PanaKare Plus500 in 1 BOTTLE, PLASTICTABLET50010

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
59051-9067PANAKARE PLUS (PANCREATIC ENZYME) TABLET [NEOGEN CORPORATION-MERCER]102 package rows20240124_c9b7ae4f-3463-4054-9ad8-b75b0bd3b20f.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
PANCRELIPASE AMYLASEACTIVE INGREDIENTYOJ58O116E3
PANCRELIPASE LIPASEACTIVE INGREDIENT8MYC33932O3
PANCRELIPASE PROTEASEACTIVE INGREDIENT3560D81V503
PANCRELIPASE AMYLASEACTIVE MOIETYYOJ58O116E3
PANCRELIPASE LIPASEACTIVE MOIETY8MYC33932O3
PANCRELIPASE PROTEASEACTIVE MOIETY3560D81V503
ALPHA-TOCOPHEROLINACTIVE INGREDIENTH4N855PNZ13
VITAMIN AINACTIVE INGREDIENT81G40H8B0T3
VITAMIN DINACTIVE INGREDIENT9VU1KI44GP3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
59051-906759051-9067-7, 59051-9067-5

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 10 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1TABLET / ORAL2 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1OINTMENT / TOPICALNAExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1TABLET, EXTENDED RELEASE / ORAL4 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS0.64 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1TABLET, CHEWABLE / ORAL0.1 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1SOLUTION / ORAL1.05 mg/1mlExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1SYSTEM / TOPICAL0.1 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1FILM, SOLUBLE / BUCCAL0.07 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1TABLET, FILM COATED / ORAL246 mgExact identifier — unii candidate
10 equally ranked IID candidates
ALPHA-TOCOPHEROL.ALPHA.-TOCOPHEROLH4N855PNZ1CAPSULE / ORAL16 mgExact identifier — unii candidate
10 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.